NASDAQ:SION Sionna Therapeutics Q3 2026 Earnings Results & Report $3.72 +0.16 (+4.34%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. Sionna Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.72 versus the -$0.62 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 10, 2026TimeBefore Market OpensConference Call7:00 AM ET Sionna Therapeutics EPS ResultsActual EPS-$0.72Consensus EPS -$0.62Beat/MissMissed by -$0.10One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersSionna Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Sionna Therapeutics Q3 2026 Earnings FAQ Did Sionna Therapeutics beat earnings estimates for Q3 2026? Sionna Therapeutics (NASDAQ:SION) reported earnings of -$0.72 per share for Q3 2026, missing the consensus estimate of -$0.62. The report was announced on Tuesday, November 10, 2026. Sionna Therapeutics Earnings HeadlinesSionna Therapeutics Q3 2026: Miss, Layoffs, and a 2029 Cash Runway4 hours ago | 247wallst.comSionna Therapeutics Reports Third Quarter 2026 Financial ResultsNovember 10 at 7:00 AM | globenewswire.comMy prediction for December 8thElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 10 at 1:00 AM | Behind the Markets (Ad)Sionna Therapeutics: The Market May Be Wrong About The Science, But Right About The StockNovember 6, 2026 | seekingalpha.comSionna Therapeutics to Participate in Upcoming November 2026 Investor ConferencesNovember 2, 2026 | globenewswire.comSionna Therapeutics, Inc. (NASDAQ:SION) Stock Has Average Target Price of $42.33November 2, 2026 | americanbankingnews.comSee More Sionna Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sionna Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sionna Therapeutics and other key companies, straight to your email. Email Address About Sionna TherapeuticsSionna Therapeutics (NASDAQ:SION) is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disorder that affects the lungs and other organs. The company is working to address the underlying cause of CF by developing small-molecule therapies designed to improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s research centers on the nucleotide-binding domain 1 (NBD1) of CFTR, which plays an important role in the protein’s structure and activity. Its pipeline includes investigational CFTR modulators intended to correct defects associated with disease-causing mutations, including the F508del mutation, with the goal of potentially treating a broad range of people with cystic fibrosis. The company’s programs remain investigational and are being evaluated through preclinical and clinical development activities. Sionna Therapeutics focuses on advancing its CFTR-modulator portfolio toward potential therapies for patients whose disease may not be adequately addressed by existing treatments.View Sionna Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
